The €25M to €250M Sweet Spot: Why Europe's HealthTech Mid-Market Is Where Private Equity Returns Are Being Made in 2026

Nelson Advisors
8 hours ago
10 min read

Average HealthTech deal size has more than tripled since 2022, but the entry multiples that make a fund's vintage are still found below €250M EV.

Global and European healthcare M&A surged in 2025, with global transaction value reaching $546.7 billion, a 38% increase year-over-year. In Europe, private equity healthcare buyout value reached $80.9 billion in 2025 and is projected to surpass $95.0 billion in 2026. Disclosed global healthcare buyout value exceeded $191 billion in 2025, propelled by pent-up capital deployment and large platform transactions exceeding $1 billion in Enterprise Value (EV).

However, headline deployment numbers mask a bifurcated market. In the mega-cap space, intense competition among bulge-bracket sponsors and strategic acquirers has driven entry multiples to 15x–25x EBITDA. At these valuations, achieving hurdle rates requires aggressive leverage and near-flawless operational execution.

Genuine alpha and upper-quartile Multiple on Invested Capital (MOIC) are concentrated in the lower-to-middle market (LMM): European targets valued between €25 million and €250 million EV, generating €1 million to €10 million in operating EBITDA.

These founder-led businesses trade at entry multiples of 10x–14x EBITDA, offering institutional sponsors insulation from competitive public auctions, structural inefficiency in target advisory, and an abundant supply of high-margin assets ready for buy-and-build expansion.

The Macro Divergence: Deal Volume vs. Value Concentration

The European healthcare private equity ecosystem is defined by a divergence between transaction volume and total capital value. While aggregate deal value rebounded sharply in 2025, overall global transaction volume contracted from 4,209 deals in 2024 to 4,018 in 2025. Although European buyout volume surpassed its 2021 peak due to small-cap activity, capital allocation has increasingly concentrated into scaled platform buyouts.

This concentration reflects a "flight to scale" among mega-cap financial sponsors. Fearing mid-market operational friction, public market volatility, and complex regulatory transitions, large funds have prioritized multi-billion-dollar de-risked assets. As a result, average European HealthTech transaction size expanded from $13.6 million in early 2022 to an estimated $46.6 million by early 2026.

Market Parameter	Lower Mid-Market Sweet Spot (€25M–€250M EV)	Large-Cap / Mega-Cap Segment (>€250M EV)	Strategic Implication for PE Sponsors
Target Revenue Range	€5.0M – €50.0M	>€100.0M	Mid-market targets present manageable scale for operational restructuring.
Operating EBITDA	€1.0M – €10.0M	>€25.0M – €100.0M+	Lower EBITDA targets allow entry prior to institutional size premiums.
FTE Employee Base	20 – 250 Employees	>1,000 Employees	Leaner employee footprints permit rapid post-acquisition repositioning.
Average Entry Multiple (EV/EBITDA)	10.0x – 14.0x	15.0x – 25.0x	Mid-market assets offer a 5 to 10 turn EBITDA entry discount.
Auction Dynamics	Bilateral / Limited Process	Highly Competitive / Bulge Bank Auctions	Inefficient discovery creates opportunities for off-market sourcing.
Primary Value Vector	Buy-and-Build & Multiple Arbitrage	International Scale & Cost Rationalization	Mid-market platforms capture value step-ups crossing the €10M EBITDA mark.

This capital concentration at the top of the pyramid leaves the lower mid-market less crowded. Mandate restrictions prevent mega-cap funds from deploying equity into targets under €50M EV without prior platform aggregation. Consequently, targets generating €1M to €10M in EBITDA trade at structural discounts, providing mid-market sponsors with entry points that protect downside risk while preserving significant upside potential.

Valuation Asymmetries: The Multiple Arbitrage Engine Below €250M EV

The financial thesis for investing in European HealthTech targets with €1M to €10M EBITDA rests on systematic multiple arbitrage. Empirical valuation data across European healthcare transactions demonstrates a steep non-linear step-up in valuation multiples once a business crosses institutional EBITDA thresholds.

Software and digital health targets generating $1M–$3M (€0.9M–€2.8M) in annual EBITDA trade at median entry multiples of 8.2x EBITDA. As scale increases to $3M–$5M EBITDA, multiples rise to 10.2x, reaching 14.4x for assets generating $5M–$10M EBITDA.

Once a consolidated platform crosses the $10 million (€9.2 million) EBITDA boundary, institutional demand expands valuations to 14.0x–18.0x EBITDA, while large-cap platforms exceeding $100 million EBITDA trade at 18.0x–25.0x.

Small-Cap Target (€1M–€3M EBITDA)

Entry Multiple: 8.0x–10.0x EBITDA

▼

Platform Consolidation (Buy-and-Build Add-ons)

Operational Scaling & Cross-Border Expansion

▼

Institutional Platform (€10M+ EBITDA)

Exit Multiple: 14.0x–18.0x EBITDA

▼

Value Realisation: 4.0x–6.0x Multiple Expansion

+Earnings Growth Compounding

This valuation curve allows PE sponsors to generate outsized returns through structured buy-and-build execution. By acquiring a core platform in the €25M–€100M EV range (at 10x–12x EBITDA) and completing lower-multiple add-on acquisitions (at 6x–8x EBITDA), sponsors can build pan-European platforms generating over €15 million in EBITDA. Selling the consolidated platform to a large-cap sponsor or strategic acquirer captures 4 to 6 turns of multiple expansion alongside underlying earnings growth.

HealthTech Sub-Sector	EV / Revenue Multiple (2026 Outlook)	EV / EBITDA Multiple (2026 Outlook)	Primary Valuation Drivers & Value Catalysts
AI-Native Clinical & Diagnostic Solutions	6.0x – 8.0x+	14.0x – 20.0x	Proprietary algorithms, "Glass Box" interpretability, EU AI Act conformity.
Data Monetization & Interoperability	5.5x – 7.0x	12.0x – 15.0x	EHDS secondary data readiness, native EHR integration, real-world data curation.
Value-Based Care (VBC) Platforms	5.5x – 7.0x	11.0x – 18.0x	Demonstrated ROI for payers, NHS savings alignment, reimbursement pathway lock-in.
General HealthTech SaaS	4.0x – 6.0x	10.0x – 13.0x	Rule of 40 score, high Net Retention Rates (NRR >105%), low gross churn.
MDR-Ready MedTech Hardware	3.5x – 5.0x	11.0x – 14.0x	Completed Class III MDR/IVDR certifications, supply chain resilience, recurring consumables.
Revenue Cycle Management (RCM) / HCIT	3.5x – 5.0x	16.0x – 22.0x	Back-office automation, provider cash flow optimization, roll-up potential.
Unprofitable / Early-Stage Digital Health	3.0x – 4.0x	N/A (Distressed)	High cash burn, unproven unit economics, urgent need for recapitalization.

Underwriting discipline has pivoted decisively from pure top-line expansion toward efficient growth. In 2026, HealthTech assets are evaluated against a profit-weighted "Rule of 40" model, where the sum of annual revenue growth rate and operational EBITDA margin must exceed 40% to command premium valuations.

Historical return data validates this sector emphasis: between 2017 and 2025, European Healthcare IT buyouts delivered a median MOIC of 2.3x, outperforming biopharma (2.1x), provider facilities (1.9x), and traditional MedTech (1.9x).

The Advisory Gap: Exploiting Information Asymmetry in Lower Mid-Market Transactions

A primary driver of attractively priced deal flow in the European €25M–€250M HealthTech segment is the persistent "advisory gap". This structural market gap stems from two distinct institutional limitations:

Bulge-Bracket Disinterest: Global investment banks operate with fee structures that make targets under €250M EV economically unviable to service, leaving lower mid-market assets off the radar of broad global auctions.
Generalist Advisory Limitations: Local, generalist mid-market corporate finance boutiques frequently lack the domain-specific expertise required to evaluate complex HealthTech and MedTech assets. Generalist advisors struggle to underwrite clinical software architecture, regulatory pathways, reimbursement coding, and cross-border data privacy standards, often mispricing assets or failing to structure competitive sell-side processes.

This dynamic creates an informational asymmetry that specialized private equity sponsors can systematically exploit. Founder-led businesses—which form the core of the European healthcare technology sector—often reach €5 million to €30 million in revenue without raising formal venture capital or engaging investment bankers.

Founders are frequently overwhelmed by the operational complexity of European expansion, software compliance, and national healthcare system integrations, making them receptive to direct, partner-led sponsor outreach.

Specialised private equity sponsors bridge this gap by partnering with dedicated healthcare advisory boutiques and regulatory due diligence firms. These technical specialists conduct detailed audits of target quality management systems, clinical evaluation reports, and software architectures prior to exclusivity. Consequently, informed sponsors can identify de-risked clinical assets disguised as complex, underbanked businesses, acquiring them through bilateral negotiations at attractive entry valuations.

Sourcing Map of Underbanked European HealthTech Sub sectors

Capturing value in the lower mid-market requires targeting subsectors characterized by high technical barriers to entry, regulatory tailwinds, and fragmented market structures.

AI-Native Clinical & Diagnostic Workflow Solutions

While generic AI applications face valuation compression, specialized clinical workflow platforms command premium pricing. Key targets in this subsector include specialized pathology, radiology, and oncology decision-support software. Value creation hinges on "glass box" algorithmic interpretability that complies with European regulatory standards while directly accelerating diagnostic throughput for hospital networks facing severe staffing shortages.

Data Monetisation & Interoperability Infrastructure

The implementation of the European Health Data Space (EHDS) framework has transformed fragmented electronic health record (EHR) data into a highly regulated asset class. Mid-market targets offering secure middleware, anonymised real-world data curation, and cross-border health data exchange serve as essential infrastructure layers across national health systems. These platforms generate recurring software revenues with gross margins exceeding 75%.

MDR-Ready MedTech Hardware & Connected Devices

The European Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) implementations have created significant compliance barriers. Many founder-led MedTech companies with clinically proven active implantables, surgical robotics, or diagnostic hardware lack the regulatory resources required to navigate complex re-certification processes.

Sponsors capable of funding and executing regulatory compliance can acquire these targets at discounted multiples (8x–11x EBITDA), unlocking immediate equity value upon securing formal certification.

Revenue Cycle Management (RCM) & Back-Office HCIT

Hospital administration across Europe remains burdened by legacy manual workflows. Mid-market platforms offering automated patient scheduling, clinical coding, and revenue cycle management address acute labor shortages across European provider networks. RCM targets offer predictable SaaS revenues, defensible customer retention rates (>95%), and significant consolidation potential.

Sub sector Category	Target Profile & Geography	Primary Regulatory / Operational Tailwind	Typical Deal Sourcing Mode
AI-Native Diagnostics	DACH & Nordics (€2M–€8M EBITDA)	EU AI Act "Glass Box" Transparency Mandate	Direct Founder Outreach / University Spin-outs
Interoperability Layers	Benelux & UK (€1M–€5M EBITDA)	EHDS Cross-Border Data Access Mandates	Specialized Technology Advisors
Class IIb/III MedTech	DACH & France (€3M–€10M EBITDA)	MDR / IVDR Certification Deadlines	Regulatory Consultant Network Referrals
Practice Management & RCM	Southern Europe & UK (€2M–€7M EBITDA)	Provider Cost Pressures & Staff Deficits	Bilateral Regional Roll-up Strategies

Regulatory Deadlines as Catalysts for Value Creation

The regulatory environment in 2026 acts as a powerful market filter: it imposes operational friction on unprepared targets while creating defensible moats and buy-side opportunities for sophisticated sponsors. In the European healthcare technology sector, upcoming regulatory enforcement deadlines serve as direct catalysts for mid-market dealmaking.

FDA QMSR Harmonization (February 2026): The FDA's Quality Management System Regulation harmonizes US 21 CFR Part 820 with international standard ISO 13485. European mid-market MedTech targets with robust ISO 13485 systems can seamlessly access the US market, increasing their attractiveness as acquisition targets for US strategic buyers and boosting exit multiples by 15% to 20%.
EU AI Act Enforcement (March 2026): Mandates strict "glass box" model interpretability, data governance, and bias audits for clinical artificial intelligence systems. Targets relying on unexplainable "black box" algorithms face steep valuation discounts (30%–40%) or deal exclusion. Conversely, compliant AI platforms command scarcity premiums reaching 6.0x–8.0x+ revenue.
MDR / IVDR Class III Deadline (May 26, 2026): Represents the final enforcement deadline for high-risk Class III medical devices under the EU Medical Device Regulation. Unfunded targets unable to complete updated clinical evaluation reports face regulatory distress. Sponsors capable of injecting growth capital to finalize certifications can acquire assets at deep discounts and capture immediate multiple expansion upon compliance approval.
Mandatory EUDAMED Registration (May 28, 2026): Mandatory registration in the European Database on Medical Devices becomes a prerequisite for commercial distribution and M&A exits. Targets with fully compliant EUDAMED filings avoid exit delays, maintaining transaction momentum during sell-side processes.

Tactical Sourcing and Execution: Why Proprietary Deal Flow Persists

A critical question for institutional LPs is why proprietary, off-market deal flow persists in European HealthTech despite high levels of sponsor dry powder. The answer lies in the structural fragmentation of the European landscape.

Unlike the unified US market, Europe comprises over 27 distinct healthcare systems, language regions, and reimbursement models (such as DiGA in Germany, PECAN in France, and the NHS framework in the UK). A founder who has successfully scaled a HealthTech business to €15 million in revenue within the DACH region frequently encounters operational barriers when attempting to expand into France or the UK. These multi-jurisdictional hurdles often induce founder fatigue.

Founders at this inflection point rarely want a complete cash-out sale. Lower mid-market PE sponsors structure deals offering partial liquidity combined with significant rollover equity (typically 20% to 40%) into a consolidated pan-European platform. This aligns incentives, allowing founders to participate in the value created by international expansion, professionalized management, and buy-and-build roll-ups.

By establishing direct relationships with founders through specialized regional teams and avoiding formal corporate auctions, mid-market sponsors secure proprietary entry valuations of 10x–12x EBITDA. This systematic sourcing discipline underpins consistent fund outperformance across economic cycles.

Conclusions and Strategic Execution Framework

The 2026 European healthcare private equity market presents a clear strategic choice: while mega-cap platform valuations remain crowded and fully priced, lower mid-market HealthTech targets (€25M–€250M EV) offer an attractive risk-adjusted risk/return profile.

Sourcing founder-led assets generating €1M to €10M in EBITDA allows sponsors to deploy capital at reasonable entry multiples while capturing structured, multi-turn valuation expansion.

To systematically generate alpha in this market segment, private equity sponsors should execute a four-part strategy:

Target High Regulatory Moats: Allocate capital to AI-native clinical tools ("glass box" architectures), EHDS data interoperability infrastructure, and MDR-certified clinical hardware where regulatory compliance establishes sustainable competitive barriers.
Exploit the Advisory Gap: Build direct sourcing networks and leverage specialized regulatory advisors to identify underbanked, founder-led targets across fragmented European markets before they enter broad sell-side auctions.
Drive Buy-and-Build Multiple Arbitrage: Acquire core regional platforms at 10x–12x EBITDA and execute strategic add-on acquisitions at lower multiples to aggregate EBITDA past the institutional €10M threshold.
Underwrite Profit-Weighted Growth: Transition portfolio companies from top-line growth metrics toward balanced Rule of 40 performance, targeting high Net Retention Rates (>105%) and strong EBITDA conversion.

By bridging the advisory gap, navigating complex regulatory transitions, and consolidating fragmented regional assets into pan-European platforms, mid-market private equity sponsors can generate superior returns and set the benchmark for European healthcare investing in 2026 and beyond.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics